Article
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.
Melanoma research - 1 Dec 2017
Hallmeyer Sigrun, Gonzalez Rene, Lawson David H, Cranmer Lee D, Linette Gerald P, Puzanov Igor, Taback Bret, Cowey C Lance, Ribas Antoni, Daniels Gregory A, Moore Timothy, Gibney Geoffrey T, Tawbi Hussein, Whitman Eric, Lee Geraldine, Mun Yong, Liu Shiyao, Hamid Omid
Abstract excerpt
BRAF mutations are found in ~50% of metastatic melanomas, most commonly in codon V600. Vemurafenib improves progression-free survival and overall survival in patients with advanced BRAF-mutated melanoma. The results of a descriptive study evaluating vemurafenib in patients with advanced melanoma harbouring BRAF mutations other than V600E are reported. Eligible patients with stage IIIC or IV melanoma and non-V600E...
Topics
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Female
- Humans
- Indoles
- Male
- Melanoma
- Middle Aged